Moximed receives FDA marketing authorization of implantable shock absorber for knee OA
Click Here to Manage Email Alerts
Key takeaways:
- Moximed received FDA marketing authorization of its Misha knee system.
- The system is designed for patients with symptomatic knee osteoarthritis who failed operative or nonoperative treatment.
Moximed has announced FDA marketing authorization of its Misha knee system, an implantable shock absorber for patients with knee osteoarthritis, according to a company press release.
The Misha knee system is designed to treat patients with medial knee OA who remain symptomatic after failed operative or nonoperative treatment.
“This is a milestone event for knee OA sufferers, and it’s the result of unwavering clinical research and development that spans more than 10 years,” Anton Clifford, PhD, founder and CEO of Moximed, said in the release. “We’re thrilled to now be in a position to make the surgery available to patients. We are committed to providing excellent medical education and customer service, supporting selection and treatment of indicated patients, and demonstrating scalability of our business as we introduce the Misha knee system to the U.S.,” Clifford said.
Read more about
Click Here to Manage Email Alerts